Objective:
Primary:
In the RAS (G12X-C) population, i.e., RAS G12X excluding G12C:
- To compare the treatment effect of RMC-6236 versus docetaxel on:
- PFS (per Investigator)
- OS
Key Secondary
In the RAS (MUT) population:
- To compare the treatment effect of RMC-6236 versus docetaxel on:
- PFS (per Investigator)
- OS
In the RAS (G12X-C) and RAS (MUT) populations:
- To compare the treatment effect of RMC-6236 versus docetaxel on objective response (per Investigator)
Other Secondary
In the RAS (G12X-C) and RAS (MUT) populations:
- To compare the treatment effect of RMC-6236 versus docetaxel on:
- PFS (per BICR)
- Objective response (per BICR)
In the RAS (G12X-C) and RAS (MUT) populations:
- To compare the treatment effect of RMC-6236 versus docetaxel on:
- DOR (per Investigator and per BICR)
- TTR (per Investigator and per BICR)
In the RAS (G12X-C) and RAS (MUT) populations:
- To compare the treatment effect of RMC-6236 versus docetaxel on QoLs using EORTC QLQ-LC13 and EORTC QLQ-C30
In the RAS (G12X-C) and RAS (MUT) population:
- To compare safety and tolerability of RMC-6236 versus docetaxel
In the RAS (MUT) population:
- To characterize the PK of RMC-6236